Luopu Biotech (02157) achieves first half-year profit! It is expected that the mid-term profit will exceed 24 million yuan by 2025.

LEPU BIO-B (02157) Board of Directors announces to the company's shareholders and potential investors that, based on a preliminary assessment of the unaudited consolidated financial statements for the six months ended June 30, 2025, and the information currently available to the Board of Directors, the company is expected to achieve a profit of not less than 24 million RMB. This marks a significant turnaround from the approximately 197 million RMB loss in the same period in 2024, achieving profitability for the first time. During the reporting period, the main reason for LEPU BIO's return to profit was a significant increase in revenue, including licensing revenue from the collaboration with ArriVent BioPharma (AVBP.US) on the drug MRG007, as well as sales revenue from Purporintin (Purpertinib injection) also making important contributions to the company's profitability. Established in 2018, LEPU BIO focuses on the research and commercialization of innovative biopharmaceuticals and ADCs (Antibody-Drug Conjugates) in the field of oncology. Currently, the company's pipeline has formed a layout of ADC+immune+oncolytic virus, with PD-1 (Purpertinib) already approved and on the market, and the core drug MRG003 in the pipeline being the first domestically declared EGFR ADC for listing. In addition to MRG003, the highlights of LEPU BIO's ADC drugs include MRG004A, MRG006A, and MRG007. Among them, MRG004A (TF ADC) is actively exploring indications for pancreatic cancer, and has already initiated a Phase III clinical trial; MRG006A is the world's first clinical stage GPC3 ADC, with Phase I/II clinical studies currently being conducted at multiple medical centers nationwide; recently, MRG007 (CDH17 ADC) with potential FIC/BIC success has also successfully enrolled its first patient. In recent years, LEPU BIO has been continuously engaged in overseas transactions. In 2023, LEPU BIO/Conioya's CLDN18.2 ADC product CMG901 was licensed to Astrazeneca PLC Sponsored ADR for a total of 1.188 billion USD, while in early 2025, the CDH17 ADC pipeline MRG007 was licensed to ArriVent BioPharma for over 1.2 billion USD. This month, the preclinical TCE assets with a potential total transaction amount of 850 million USD and holding 10% equity in the partnership company were acquired by Excalipoint, demonstrating the company's innovative research and development capabilities are fully recognized by MNCs and overseas capital.